Compare Nutrien Ltd (NTR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Novartis AG — how do they compare? Nutrien Ltd trades at $70.4 (market cap $33.31B), while Novartis AG trades at $143.81 (market cap $268.57B). The key difference: Novartis AG is far larger — about 8.1× Nutrien Ltd's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Novartis AG for 82 Days on average.
| NTR | NVS | |
|---|---|---|
Market Cap | $33.31B | $268.57B |
Volume | 1,330,729 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $168.62 |
52-Week Low | $53.64 | $121.80 |
Typical Hold Time | 59 Days | 82 Days |
Enterprise Value | $45.11B | $309.89B |
Dividend Yield | 3.15% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.97, down 1.73% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation at P/E of 14.14. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations, while analyst consensus remains bullish with $76.14 price target.
NTR presents value opportunity with reasonable valuation and strong agricultural market positioning, though faces headwinds from fertilizer price volatility and competitive pressures. The stock's current discount to analyst targets and oversold technical condition suggest potential upside, but investors should monitor input cost trends and global fertilizer demand dynamics closely.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
